• The empirical likelihood prior applied to bias reduction of general estimating equations.

  Vexler A, Zou L, Hutson AD.
  Comput Stat Data Anal. 2019 Oct;138:96-106. doi: 10.1016/j.csda.2019.04.001.

• Whole-Exome Sequencing Of Ovarian Cancer Families Uncovers Putative Predisposition Genes.

  Zhu Q, Zhang J, Chen Y, Hu Q, Shen H, Huang RY, Liu Q, Kaur J, Long M, Battaglia S, Eng KH, Lele SB, Zsiros E, Villella J, Lugade A, Yao S, Liu S, Moysich K, Odunsi KO.
  Int J Cancer. 2019 Jul 2. doi: 10.1002/ijc.32545.

• Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer.

  Liu S, Matsuzaki J, Wei L, Tsuji T, Battaglia S, Hu Q, Cortes E, Wong L, Yan L, Long M, Miliotto A, Bateman NW, Lele SB, Chodon T, Koya RC, Yao S, Zhu Q, Conrads TP, Wang J, Maxwell GL, Lugade AA, Odunsi K.
  J Immunother Cancer. 2019 Jun 20;7(1):156. doi: 10.1186/s40425-019-0629-6.

• Accurate Quantification of Residual Cancer Cells in Pelvic Washing Reveals Association with Cancer Recurrence Following Robot-Assisted Radical Cystectomy.

  Wei L, Hussein AA, Ma Y, Azabdaftari G, Ahmed Y, Wong LP, Hu Q, Luo W, Cranwell VN, Bunch BL, Kozlowski JD, Singh PK, Glenn ST, Smith G, Johnson CS, Liu S, Guru KA.
  J Urol. 2019 Jun;201(6):1105-1114. doi: 10.1097/JU.0000000000000142.

• HMMRATAC: a Hidden Markov ModeleR for ATAC-seq.

  Tarbell ED, Liu T.
  Nucleic Acids Res. 2019 Jun 14. pii: gkz533. doi: 10.1093/nar/gkz533.

• A robust Pearson correlation test for a general point null using a surrogate bootstrap distribution.

  Hutson AD.
  PLoS One. 2019 May 16;14(5):e0216287. doi: 10.1371/journal.pone.0216287.

• Engineering the TGFβ receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma.

  Burga RA, Yvon E, Chorvinsky E, Fernandes R, Cruz CR, Bollard CM.
  Clin Cancer Res. 2019 Apr 22. pii: clincanres.3183.2018. doi: 10.1158/1078-0432.CCR-18-3183.

• MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells.

  Yamamoto M, Jin C, Hata T, Yasumizu Y, Zhang Y, Hong D, Maeda T, Miyo M, Hiraki M, Suzuki Y, Hinohara K, Rajabi H, Kufe D.
  Cancer Res. 2019 Apr 15;79(8):2031-2041. doi: 10.1158/0008-5472.CAN-18-3259.

• Preclinical Characterization of ^86/90Y-NM600 in a variety of murine and human cancer tumor models.

  Grudzinski JJ, Hernandez R, Marsh I, Patel R, Aluicio-Sarduy E, ENgle J, Morris Z, Bednarz B, Weichert JP.
  J Nucl Med. 2019 Apr 6. pii: jnumed.118.224808. doi: 10.2967/jnumed.118.224808.

• Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer.

  Kumar R, Bhat TA, Walsh EM, Chaudhary AK, O'Malley J, Rhim JS, Wang J, Morrison CD, Attwood K, Bshara W, Mohler JL, Yadav N, Chandra D.
  Cancer Res. 2019 Apr 1;79(7):1353-1368. doi: 10.1158/0008-5472.CAN-18-2383.

• Early-onset triple-negative breast cancer in multiracial/ethnic populations: Distinct trends of prevalence of truncation mutations.

  Liu Q, Yao S, Zhao H, Hu Q, Kwan ML, Roh JM, Ambrosone CB, Kushi LH, Liu S, Zhu Q.
  Cancer Med. 2019 Apr;8(4):1845-1853. doi: 10.1002/cam4.2047.

• Deep-learning augmented RNA-seq analysis of transcript splicing.

  Zhang Z, Pan Z, Ying Y, Zhijie X, Adhikari S, Phillips J, Carstens RP, Black DL, Wu Y, Xing Y.
  Nat Methods. 2019 Apr;16(4):307-310. doi: 10.1038/s41592-019-0351-9.

• NR4A transcription factors limit CAR T cell function in solid tumours.

  Chen J, Lopez-Moyado IF, Seo H, Lio CJ, Hempleman LJ, Sekiya T, Yoshimura A, Scott-Browne JP, Rao A.
  Nature. 2019 Mar;567(7749):530-534. doi: 10.1038/s41586-019-0985-x.

• Genomic correlates of response to immune checkpoint blockade.

  Keenan TE, Burke KP, Van Allen EM.
  Nat Med. 2019 Mar;25(3):389-402. doi: 10.1038/s41591-019-0382-x.

• ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.

  Cao Y, Trillo-Tinoco J, Sierra RA, Anadon C, Dai W, Mohamed E, Cen L, Costich TL, Magliocco A, Marchion D, Klar R, Michel S, Jaschinski F, Reich RR, Mehrotra S, Cubillos-Ruiz JR, Munn DH, Conejo-Garcia JR, Rodriguez PC.
  Nat Commun. 2019 Mar 20;10(1):1280. doi: 10.1038/s41467-019-09263-1.

• Impact of chemotherapy for breast cancer on leukocyte DNA methylation landscape and cognitive function: a prospective study.

  Yao S, Hu Q, Kerns S, Yan L, Onitilo AA, Misleh J, Young K, Lei L, Bautista J, Mohamed M, Mohile SG, Ambrosone CB, Liu S, Janelsins MC.
  Clin Epigenetics. 2019 Mar 12;11(1):45. doi: 10.1186/s13148-019-0641-1.

• Discovery of Allele-Specific Protein-RNA Interactions in Human Transcriptomes.

  Bahrami-Samani E, Xing Y.
  Am J Hum Genet. 2019 Mar 7;104(3):492-502. doi: 10.1016/j.ajhg.2019.01.018

• ⁹⁰Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin's Lymphoma.

  Hernandez R, Walker KL, Grudzinski JJ, Aluicio-Sarduy E, Patel R, Zahm CD, Pinchuk AN, Massey CF, Bitton AN, Brown RJ, Sondel PM, Morris ZS, Engle JW, Capitini CM, Weichert JP.
  Commun Biol. 2019 Feb 26;2:79. doi: 10.1038/s42003-019-0327-4.

• Mitochondrial hypoxic stress induces widespread RNA editing by APOBEC3G in natural killer cells.

  Sharma S, Wang J, Alqassim E, Portwood S, Cortes Gomez E, Maguire O, Basse PH, Wang ES, Segal BH, Baysal BE.
  Genome Biol. 2019 Feb 21;20(1):37. doi: 10.1186/s13059-019-1651-1.

• Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.

  Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon Aj, Kinsbury GA, Fong L.
  Immunity. 2019 Feb 19;50(2):477-492.e8. doi: 10.1016/j.immuni.2019.01.006.

• Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.

  Hanoteau A, Newton JM, Krupar R, Huang C, Liu HC, Gaspero A, Gartrell RD, Saenger YM, Hart TD, Santegoets SJ, Laoui D, Spanos C, Parikh F, Jayaraman P, Zhang B, Van der Burg SH, Van Ginderachter JA, Melief CJM, Sikora AG.
  J Immunother Cancer. 2019 Jan 15;7(1):10. doi: 10.1186/s40425-018-0485-9.

• Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?

  Febbraio MA, Reibe S, Shalapour S, Ooi GJ, Watt MJ, Karin M.
  Cell Metab. 2019 Jan 8;29(1):18-26. doi: 10.1016/j.cmet.2018.10.012.

• Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens.

  Miller A, Bahmanof M, Zehn D, Cohen E, Schoenberger S.
  Cancer Immunol Res. 2019 Jan;7(1):40-49. doi: 10.1158/2326-6066.